Teri Foy, PhD, Senior Vice President, Cancer Immunology and Cell Therapy Thematic Research Center and Seattle site lead, and Mike Burgess, MD, PhD, Senior Vice President, Head of Translational Medicine, Bristol Myers Squibb, discuss the challenges, progress, and potential of CAR T-cell therapy. Cell therapy research is now advancing beyond cancer to target cells contributing to other chronic diseases.
Xavier Leleu, MD, PhD, Poitiers University Hospital, Poitiers, France, discusses findings from one arm of the Phase 2 KarMMA-2 trial that was designed to investigate idecabtagene vicleucel in…
Barry Paul, MD, Atrium Health Levine Cancer Institute, Charlotte, North Carolina, discusses research related to idecabtagene vicleucel treatment for patients with newly diagnosed multiple myeloma and suboptimal responses…
Manali Kamdar, MD, clinical director of lymphoma services, University of Colorado Cancer Center, Denver, Colorado, discusses the use of circulating tumor DNA as an early predictor of outcomes…
Jennifer Crombie, MD, Dana-Farber Cancer Institute, Boston, Massachusetts, discusses results from a real-world study of lisocabtagene maraleucel in patients with relapsed/refractory large B-cell lymphoma. Similar to published findings…
Michaela Liedtke, MD, of @StanfordMed, discusses #CARTcell #immunotherapy for #multiplemyeloma.Michaela Liedtke, MD, of @StanfordMed, discusses #CARTcell #immunotherapy for #multiplemyeloma.
Krina K. Patel, MD, MSc, associate professor, Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas, discusses results from a recent study of real-world…
Rahul Banerjee, MD, assistant professor, Clinical Research Division, University of Washington Fred Hutchinson Cancer Center, Seattle, Washington, addresses the question of whether CAR T-cell therapy is a cure…
Jae H. Park, MD, hematologic oncologist and attending physician at the Leukemia Service and Cellular Therapeutics Center of Memorial Sloan Kettering Cancer Center, discusses the future of chimeric…
Praneeth Reddy Sudalagunta, PhD, applied research scientist, Moffitt Cancer Center, Tampa, Florida, discusses the differential effects of bridging therapy on the immune microenvironment as well as outcomes with…